The putative anlotinib target pathway, vascular endothelial growth factor (VEGF) signaling pathway11,12, was also significantly altered after anlotinib treatment of two ICC cell lines (Fig. 4c). The gene discussed is VEGFA; the disease is intrahepatic cholangiocarcinoma.